Working memory impairment as a common component in recurrent depressive disorder and certain somatic diseases

Neuroendocrinology Letters

Volumn 34, Issue 5, 2013, Pages 436-445

  Gałecki, Piotr ^a   Talarowska, Monika ^a   Moczulski, Dariusz ^a   Bobińska, Kinga ^a   Opuchlik, Katarzyna ^a   Głaecka, Elzbieta ^a   Florkowski, Antoni ^a   Lewiński, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Arterial hypertension; Cognitive functions; Depressive disorders; Diabetes; Working memory

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CLINICAL EFFECTIVENESS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL DETERIORATION; NITROSATIVE STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PSYCHOLOGIC TEST; PSYCHOSOMATIC DISORDER; RECURRENT DISEASE; STROOP TEST; WORKING MEMORY;

EID: 84884957031     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Alley DE, Crimmins EM, Karlamangla A, Hu P, Seeman TE (2008). Inflammation and rate of cognitive change in high-functioning older adults. J Gerontol A Biol Sci Med Sci 63: 50-55. (Pubitemid 351738463)
2. Arosio B, Mastronardi L, Gussago C, Nicolini P, Casč A, Ziglioli E, et al. (2011). Adenosine A(2A) receptor and IL-10 in peripheral blood mononuclear cells of patients with Mild Cognitive Impairment. Int J Alzheimer's Dis 2011: 1-6.
3. Audenaert K, Lohorte P, Brans B, Van Laere K, Goethals I, van Heeringen K, et al. (2001). The classical Stroop interference task as a prefrontal activation probe: a validation study using 99Tcm-ECD brain SPECT. Nucl Med Commun 22: 135-143. (Pubitemid 32222628)
4. Bartels AL, Willemsen AT, Kortekaas R, de Jong BM, de Vries R, de Klerk O, et al. (2008). Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. J Neural Transm 115: 1001-1009.
5. Berger JR, Nath A, Greenberg RN, Andersen AH, Greene RA, Bognar A, et al. (2000). Cerebrovascular changes in the basal ganglia with HIV dementia. Neurology 54: 921-926. (Pubitemid 30111353)
6. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006). Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol 5: 64-74. (Pubitemid 41790697)
7. Broadway JM, Engle RW (2011). Individual differences in working memory capacity and temporal discrimination. PLoS One 6: 1-9.
8. Catena-Dell'Osso M, Bellantuono C, Consoli G, Baroni S, Rotella F, Marazziti D (2011). Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 18: 245-255.
9. Clinical recommendations on the management in patients with diabetes mellitus - Guidelines of the Polish Diabetological Society. (2011). Diabet Prakt. 12 suppl. A: 1-46 (In Polish).
10. Demyttenaere K, De Fruyt J (2003). Getting what you ask for: on the selectivity of depression rating scales. Psychothery Psychosom 72: 61-70. (Pubitemid 36302474)
11. Gałecki P, Maes M, Florkowski A, Lewiński A, Gałecka E, Bieńkiewicz M, et al. (2010). An inducible nitric oxide synthase polymorphism is associated with the risk of recurrent depressive disorder. J Neurosci Lett 486: 184-187.
12. Gałecki P, Maes M, Florkowski A, Lewiński A, Gałecka E, Bieńkiewicz M, et al. (2011). Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder. J Affect Disord 129: 175-182.
13. Gałecki P, Szemraj J, Bieńkiewicz M, Zboralski K, Gałecka E (2009). Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Hum Psychopharmacol 24: 277-286.
14. Grande LJ, Rudolph JL, Milberg WP, Barber CE, McGlinchey RE (2011). Detecting cognitive impairment in individuals at risk for cardiovascular disease: the "Clock-in-the-Box" screening test. Int J Geriatr Psychiatry. 26: 969-975.
15. Grassi D, Ferri L, Cheli P, Di Giosia P, Ferri C (2011). Cognitive decline as a consequence of essential hypertension. Curr Pharm Des 17: 3032-3038.
16. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
17. Hayashi K, Kurioka S, Yamaguchi T, Morita M, Kanazawa I, Takase H, et al. (2011). Association of cognitive dysfunction with hippocampal atrophy in elderly Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 94: 180-185.
18. Huber JD, VanGilder RL, Houser KA (2006). Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am J Physiol Heart Circ Physiol 291: 2660-2668.
19. ICD-10 Classification of Mental & Behavioural Disorders (1993). Geneva: World Health Organization.
20. Israeli-Korn SD, Masarwa M, Schechtman E, Abuful A, Strugatsky R, Avni S, et al. (2010). Hypertension increases the probability of Alzheimer's disease and of mild cognitive impairment in an Arab community in northern Israel. Neuroepidemiology 34: 99-105.
21. Kaneda Y (2009). Verbal working memory and functional outcome in patients with unipolar major depressive disorder. World J Biol Psychiatry 10: 591-594.
22. Korf ES, White LR, Scheltens P, Launer LJ (2004). Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia aging study. Hypertension 44: 29-34. (Pubitemid 38823483)
23. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F (2005). Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 4: 371-380. (Pubitemid 40720034)
24. Macander M, Talarowska M, Galecki P, Moczulski D, Lewinski A (2011). Selected diabetes control indicators and working memory efficacy. Neuro Endocrinol Lett 32: 518-25.
25. Maes M, Galecki P, Chang YS, Berk M (2011a). A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 35: 676-692.
26. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J (2011b). Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol Lett 32: 7-24.
27. Maes M, Leonard B, Fernandez A, Kubera M, Nowak G, Veerhuis R, et al. (2011c). (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 35: 659-663.
28. Mangiafico RA, Sarnataro F, Mangiafico M, Fiore CE (2006). Impaired cognitive performance in asymptomatic peripheral arterial disease: relation to C-reactive protein and D-dimer levels. Age Ageing 35: 60-65. (Pubitemid 43124923)
29. Manolio TA, Olson J, Longstreth WT (2003). Hypertension and cognitive function: pathophysiologic effects of hypertension on the brain. Curr Hypertens Rep. 3: 255-261. (Pubitemid 38914969)
30. Marioni RE, Stewart MC, Murray GD, Deary IJ, Fowkes FG, Lowe GD, et al. (2009). Peripheral levels of fibrinogen, C-reactive protein, and plasma viscosity predict future cognitive decline in individuals without dementia. Psychosom Med. 71: 901-906.
31. Mogi M, Horiuchi M (2011). Neurovascular coupling in cognitive impairment associated with diabetes mellitus. Circ J. 75: 1042-1048.
32. Mooijaart SP, Sattar N, Trompet S, Polisecki E, de Craen AJ, Schaefer EJ, et al. (2011). C-reactive protein and genetic variants and cognitive decline in old age: the PROSPER study. PLoS One. 6: 1-6.
33. Moonseong H, Murphy CF, Meyers BS (2007). Relationship between the Hamilton Depression Rating Scale and the Montgomery-Åsberg Depression Rating Scale in depressed elderly. Am J Geriatr Psychiatry 15: 899-905.
34. Mossello E, Ballini E, Boncinelli M, Monami M, Lonetto G, Mello AM, et al. (2011). Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities. Exp Diabetes Res. 2011: 281674.
35. Patten S (1997). Performance of the Composite International Diagnostic Interview Short Form for major depression in community and clinical samples. Chron Dis Can 3: 18-24.
36. Peltz CB, Gratton G, Fabiani M (2011). Age-related changes in electrophysiological and neuropsychological indices of working memory, attention control, and cognitive flexibility. Front Psychol 2: 190-202.
37. Primožič S, Tavčar R, Avbelj M, Dernovšek MZ, Oblak MR (2011). Specific cognitive abilities are associated with diabetes self-management behavior among patients with type 2 diabetes. Diabetes Res Clin Pract. 95: 48-54.
38. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L (2003). Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 60: 223-228. (Pubitemid 36193966)
39. Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD, et al. (2007). Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J Am Geriatr Soc. 55: 700-707. (Pubitemid 46668976)
40. Rafnsson S, Deary IJ, Whiteman MC, Rumley A, Lowe GD, Fowkes FG (2010). Haemorheological predictors of cognitive decline: the Edinburgh Artery Study. Age Ageing. 39: 217-222.
41. Ray S, Britschgi, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. (2007). Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13: 1359-1362.
42. Reitan RM (1958). The relation of the trail making test to organic brain damage. J Cons Psychol 19: 393-394.
43. Richard Jennings J, Christie IC, Muldoon MF, Ryan CM, Price JC, Meltzer CC (2010). Brain function, cognition, and the blood pressure response to pharmacological treatment. Psychosom Med. 72: 702-711.
44. Rojas-Fernandez CH, Moorhouse P (2009). Current concepts in vascular cognitive impairment and pharmacotherapeutic implications. Ann Pharmacother. 43: 1310-1323.
45. Rouder JN, Morey RD, Morey CC, Cowan N (2011). How to measure working memory capacity in the change detection paradigm. Psychon Bull Rev 18: 324-330.
46. Sánchez-Cubillo I, Periáñez J, Adrover-Roig D, Rodríguez-Sánchez J, Ríos-Lago M, Tirapu J (2009). Construct validity of the Trail Making Test: Role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. JINS 15: 438-51.
47. Serlin Y, Levy J, Shalev H (2011). Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc Psychiatry Neurol. 2011: 609202.
48. Stroop JR (1935). Studies of interference in serial verbal reactions. J Expl Psychol. 18: 643-662.
49. Talarowska M, Florkowski A, Zboralski K, Berent D, Wierzbiński P, Gałecki P (2010). Auditory-verbal declarative and operating memory among patients suffering from depressive disorders - preliminary study. Adv Med Sci. 55: 317-327.
50. Talarowska M, Florkowski A, Zboralski K, Gałecki P (2009). Cognitive functions and clinical features among diabetic patients in Polish population. Cent Eur J Med 4: 467-475.
51. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 28: 1462-1536.
52. Umur EE, Oktenli C, Celik S, Tangi F, Sayan O, Sanisoglu YS, et al. (2011). Increased iron and oxidative stress are separately related to cognitive decline in elderly. Geriatr Gerontol Int 11: 504-509.
53. Verdelho A, Madureira S, Ferro JM, Basile AM, Chabriat H, Erkinjuntti T, et al. (2007). Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry 78: 1325-30. (Pubitemid 350221411)
54. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ (2003). Low blood pressure and the risk of dementia in very old individuals. Neurology 61: 1667-1672. (Pubitemid 38020809)
55. Wild-Wall N, Falkenstein M, Gajewski PD (2011). Age-related differences in working memory performance in a 2-back task. Front Psychol. 2: 186-198.
56. Wysocki M, Luo X, Schmeidler J, Dahlman K, Lesser GT, Grossman H, et al. (2011). Hypertension is associated with cognitive decline in elderly people at high risk for dementia. Am J Geriatr Psychiatry 20: 179-187.
57. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, et al. (2004). The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292: 2237-2242. (Pubitemid 39473161)
58. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG (2008). Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359: 1897-1908.